TAGRISSO (osimertinib), tyrosine kinase inhibitor

Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in patients who acquired the EGFR T790M mutation during a previous treatment with anti-EGFR TKI.

• TAGRISSO has Marketing Authorisation in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR T790M mutation.
• The new data affect only patients who acquired the EGFR T790M mutation during their first-line treatment with anti-EGFR TKI. 
• In this case, progression-free survival was improved compared with platinum-based chemotherapy (absolute gain of 5.7 months) in patients previously treated with an anti-EGFR TKI.
• No gain in overall survival has been demonstrated to date.
• The safety profile of osimertinib is more favourable than that of platinum salt-based chemotherapy.

-